iSpecimen Inc. Operating Lease Cost
iSpecimen Inc. (ISPC) reported Operating Lease Cost of $41.06 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-14
- iSpecimen Inc. operating lease, cost for the quarter ending 2026-06-30 was $20.53K, a 0.00% change year-over-year.
- iSpecimen Inc. operating lease, cost for the quarter ending 2026-03-31 was $20.53K, a 0.00% change year-over-year.
- iSpecimen Inc. operating lease, cost for the quarter ending 2025-12-31 was $20.53K, a 0.00% decline year-over-year.
- iSpecimen Inc. operating lease, cost for the quarter ending 2025-09-30 was $20.53K, a 27.88% decline year-over-year.
- iSpecimen Inc. operating lease, cost for fiscal 2025 was $82.12K, a 41.60% decline from fiscal 2024.
- iSpecimen Inc. operating lease, cost for fiscal 2024 was $140.63K.
- iSpecimen Inc. operating lease, cost for fiscal 2022 was $164.31K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $20.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $41.06K 10-Q · filed 2026-08-14 | $61.59K derived: sum of 3 quarters · filed 2026-08-14 | $82.12K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $20.53K 10-Q · filed 2026-05-18 | $41.06K derived: sum of 2 quarters · filed 2026-05-18 | $61.59K derived: sum of 3 quarters · filed 2026-05-18 | $82.12K derived: sum of 4 quarters · filed 2026-05-18 |
| 2025-12-31 | $20.53K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $41.06K derived: sum of 2 quarters · filed 2026-04-01 | $61.59K derived: sum of 3 quarters · filed 2026-04-01 | $82.12K 10-K · filed 2026-04-01 |
| 2025-09-30 | $20.53K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | $41.06K derived: sum of 2 quarters · filed 2025-11-17 | $61.59K 10-Q · filed 2025-11-17 | $82.12K derived: sum of 4 quarters · filed 2025-11-17 |
| 2025-06-30 | $20.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $41.06K 10-Q · filed 2025-08-14 | $61.59K derived: sum of 3 quarters · filed 2025-08-14 | $90.06K derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | $20.53K 10-Q · filed 2025-05-19 | $41.06K derived: sum of 2 quarters · filed 2025-05-19 | $69.53K derived: sum of 3 quarters · filed 2025-05-19 | $117.91K derived: sum of 4 quarters · filed 2025-05-19 |
| 2024-12-31 | $20.53K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-14 | $49.00K derived: sum of 2 quarters · filed 2025-04-14 | $97.38K derived: sum of 3 quarters · filed 2025-04-14 | $140.63K 10-K · filed 2025-04-14 |
| 2024-09-30 | $28.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $76.85K derived: sum of 2 quarters · filed 2024-11-07 | $120.10K 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $48.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $91.63K 10-Q · filed 2024-08-06 | ||
| 2024-03-31 | $43.25K 10-Q · filed 2024-05-07 | |||
| 2023-09-30 | $41.08K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $82.16K derived: sum of 2 quarters · filed 2023-11-02 | $123.23K 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $41.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $82.16K 10-Q · filed 2023-08-02 | ||
| 2023-03-31 | $41.08K 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $164.31K 10-K/A · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |